Emgality for Migraine in Breastmilk

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Migraine

Interventions

DRUG

Galcanezumab

Receiving either 120mg or 300mg injections.

Trial Locations (1)

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

University of California, San Francisco

OTHER